{"protocolSection": {"identificationModule": {"nctId": "NCT04757584", "orgStudyIdInfo": {"id": "19-10020922-01"}, "secondaryIdInfos": [{"id": "K76AG064428", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/K76AG064428"}], "organization": {"fullName": "Weill Medical College of Cornell University", "class": "OTHER"}, "briefTitle": "Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF", "officialTitle": "N-of-1 Trials for Deprescribing Beta-blockers in HFpEF"}, "statusModule": {"statusVerifiedDate": "2024-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-04-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-04-28", "type": "ACTUAL"}, "completionDateStruct": {"date": "2023-04-28", "type": "ACTUAL"}, "studyFirstSubmitDate": "2021-02-12", "studyFirstSubmitQcDate": "2021-02-12", "studyFirstPostDateStruct": {"date": "2021-02-17", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2024-01-31", "resultsFirstSubmitQcDate": "2024-03-11", "resultsFirstPostDateStruct": {"date": "2024-04-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-03-11", "lastUpdatePostDateStruct": {"date": "2024-04-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Weill Medical College of Cornell University", "class": "OTHER"}, "collaborators": [{"name": "National Institute on Aging (NIA)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "In this study, we will test the feasibility of N-of-1 trials for deprescribing beta-blockers in patients with Heart Failure with Preserved Ejection Fraction. To achieve this objective we will conduct 16 4-period N-of-1 trials (on vs. off) and subsequently interview participants to better understand feasibility and pragmatism. The N-of-1 trials will be iteratively refined in real-time based on this feedback."}, "conditionsModule": {"conditions": ["Heart Failure", "Heart Failure, Diastolic", "Heart Failure With Preserved Ejection Fraction", "Cardiac Failure", "Heart Disease"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 9, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Beta Blocker ABAB Sequence", "type": "ACTIVE_COMPARATOR", "description": "This arm will follow an ABAB sequence. \"A\" representing ON beta blockers and \"B\" representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually up-titrating until reaching their home dose. Finally, during Period 4, we will again conduct a dose reduction until off of beta blockers.", "interventionNames": ["Drug: Beta blockers"]}, {"label": "Beta Blocker BABA Sequence", "type": "ACTIVE_COMPARATOR", "description": "This arm will follow a BABA sequence. \"A\" representing ON beta blockers and \"B\" representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers. Finally, during Period 4, we will up-titrate them back to their home dose of beta blockers.", "interventionNames": ["Drug: Beta blockers"]}], "interventions": [{"type": "DRUG", "name": "Beta blockers", "description": "The intervention is a two-arm crossover withdrawal/ reversal design (On \\[A\\] vs Off \\[B\\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.\n\nSubjects will be randomized into either ABAB or BABA sequences.", "armGroupLabels": ["Beta Blocker ABAB Sequence", "Beta Blocker BABA Sequence"], "otherNames": ["atenolol", "betaxolol", "bisoprolol", "metoprolol", "nebivolol", "nadolol", "propranolol", "acebutolol", "penbutolol", "pindolol", "carvedilol", "labetalol", "sotalol", "metoprolol succinate", "metoprolol tartrate"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Features of a Feasible and Pragmatic Protocol for Deprescribing N-of-1 Trials in Patients With Heart Failure With Preserved Ejection Fraction, as Measured by Qualitative Interview", "description": "Qualitative interviews were conducted to assess the feasibility and acceptability of deprescribing N-of-1 trials and participant experiences. Directed content analysis methods were used to develop relevant categories and themes from interview transcript data. Transcripts were coded and analyzed by two team members, consulting additional members to establish consensus where needed. Inter-rater reliability between coders was established.", "timeFrame": "Baseline"}, {"measure": "Features of a Feasible and Pragmatic Protocol for Deprescribing N-of-1 Trials in Patients With Heart Failure With Preserved Ejection Fraction, as Measured by Qualitative Interview", "description": "Qualitative interviews were conducted to assess the feasibility and acceptability of deprescribing N-of-1 trials and participant experiences. Directed content analysis methods were used to develop relevant categories and themes from interview transcript data. Transcripts were coded and analyzed by two team members, consulting additional members to establish consensus where needed. Inter-rater reliability between coders was established. The outcome measure data is the cumulative count of subjects who identified categories and themes from interview transcript data collected during the span of the outcome measure time frame, up to 6 times over 36 weeks.", "timeFrame": "The maximum amount of time a subject could have been assessed for this outcome measure is 6 times across 36 weeks. This outcome was measured at each end of period visit (weeks 6, 12, 18, 24, 30) and at the end of intervention (weeks 12, 18, 24, 30, or 36)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Ambulatory adults \u226565 years of age with Heart Failure with Preserved Ejection Fraction (HFpEF) according to ACC/AHA guidelines: (signs and symptoms of Heart failure \\[HF\\] and ejection fraction \\[EF\\] \u226550%)\n* Taking Beta blocker\n\nExclusion Criteria:\n\n* Alternate Causes of HFpEF Syndrome:\n\n  1. Severe valvular disease\n  2. Constrictive pericarditis\n  3. High output heart failure\n  4. Infiltrative cardiomyopathy\n* Other compelling indication for beta blocker:\n\n  1. Prior EF \\< 50%\n  2. Hypertrophic cardiomyopathy\n  3. Angina symptoms\n  4. Acute coronary syndrome, myocardial infarction or coronary artery bypass surgery in prior 3 year\n  5. History of ventricular tachycardia\n  6. Atrial arrhythmia with hospitalization for rapid ventricular response, prior 1 year\n  7. Sinus tachycardia \\> 100 beats per minute (bpm), atrial arrhythmia with ventricular rate \\>90 bpm, systolic blood pressure \\> 160 mmHg\n* Clinical instability (N-of-1 trials are appropriate for stable conditions only)\n\n  1. Decompensated HF\n  2. Hospitalized in past 30 days\n  3. Medication changes or procedures in prior 14 days (to prevent confounding from other interventions), at PI discretion\n* Estimated life expectancy \\<6 months\n* Moderate-severe dementia or psychiatric disorder precluding informed consent\n* Any condition that, in Principal Investigator's opinion, makes the patient unsuitable for study participation", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "65 Years", "stdAges": ["OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Parag Goyal, MD", "affiliation": "Weill Medical College of Cornell University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Weill Cornell Medicine", "city": "New York", "state": "New York", "zip": "10065", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Beta Blocker ABAB Sequence", "description": "This arm will follow an ABAB sequence. \"A\" representing ON beta blockers and \"B\" representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually up-titrating until reaching their home dose. Finally, during Period 4, we will again conduct a dose reduction until off of beta blockers.\n\nBeta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On \\[A\\] vs Off \\[B\\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.\n\nSubjects will be randomized into either ABAB or BABA sequences."}, {"id": "FG001", "title": "Beta Blocker BABA Sequence", "description": "This arm will follow a BABA sequence. \"A\" representing ON beta blockers and \"B\" representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers. Finally, during Period 4, we will up-titrate them back to their home dose of beta blockers.\n\nBeta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On \\[A\\] vs Off \\[B\\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.\n\nSubjects will be randomized into either ABAB or BABA sequences."}], "periods": [{"title": "On or Off Beta Blockers Up to 6 Wks", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Down-titration/Up-titration Up to 6 Wks", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Up-titration/Down-titration Up to 6 Wks", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "All 5 subjects on the ABAB Arm chose to complete the intervention phase after the completion of their 2nd period, and move onto the follow-up phase.", "numSubjects": "0"}, {"groupId": "FG001", "comment": "2 subjects on the BABA Arm chose to complete the intervention phase after the completion of their 2nd period, and move on to the follow-up phase. The remaining 2 subjects on the BABA Arm chose to continue onto a 3rd period.", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Down-titration/Up-Titration Up to 6 Wks", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "comment": "The remaining 2 subjects on the BABA Arm chose to complete the intervention phase after the completion of their 3rd period, and move on to the follow-up phase.", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Follow-up", "milestones": [{"type": "STARTED", "comment": "After each of the subjects complete their intervention phase, they proceed to a follow-up phase, which lasts for 12 months.", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Beta Blocker ABAB Sequence", "description": "This arm will follow an ABAB sequence. \"A\" representing ON beta blockers and \"B\" representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually up-titrating until reaching their home dose. Finally, during Period 4, we will again conduct a dose reduction until off of beta blockers.\n\nBeta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On \\[A\\] vs Off \\[B\\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.\n\nSubjects will be randomized into either ABAB or BABA sequences."}, {"id": "BG001", "title": "Beta Blocker BABA Sequence", "description": "This arm will follow a BABA sequence. \"A\" representing ON beta blockers and \"B\" representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers. Finally, during Period 4, we will up-titrate them back to their home dose of beta blockers.\n\nBeta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On \\[A\\] vs Off \\[B\\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.\n\nSubjects will be randomized into either ABAB or BABA sequences."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Features of a Feasible and Pragmatic Protocol for Deprescribing N-of-1 Trials in Patients With Heart Failure With Preserved Ejection Fraction, as Measured by Qualitative Interview", "description": "Qualitative interviews were conducted to assess the feasibility and acceptability of deprescribing N-of-1 trials and participant experiences. Directed content analysis methods were used to develop relevant categories and themes from interview transcript data. Transcripts were coded and analyzed by two team members, consulting additional members to establish consensus where needed. Inter-rater reliability between coders was established.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Beta Blocker ABAB Sequence", "description": "This arm will follow an ABAB sequence. \"A\" representing ON beta blockers and \"B\" representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually up-titrating until reaching their home dose. Finally, during Period 4, we will again conduct a dose reduction until off of beta blockers.\n\nBeta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On \\[A\\] vs Off \\[B\\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.\n\nSubjects will be randomized into either ABAB or BABA sequences."}, {"id": "OG001", "title": "Beta Blocker BABA Sequence", "description": "This arm will follow a BABA sequence. \"A\" representing ON beta blockers and \"B\" representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers. Finally, during Period 4, we will up-titrate them back to their home dose of beta blockers.\n\nBeta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On \\[A\\] vs Off \\[B\\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.\n\nSubjects will be randomized into either ABAB or BABA sequences."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"title": "Positive attitude towards deprescribing", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Questions/concerns about deprescribing N-of-1 trials", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Desire for patient-centered educational materials about deprescribing and N-of-1 trials", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Desire for short, pragmatic visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "PRIMARY", "title": "Features of a Feasible and Pragmatic Protocol for Deprescribing N-of-1 Trials in Patients With Heart Failure With Preserved Ejection Fraction, as Measured by Qualitative Interview", "description": "Qualitative interviews were conducted to assess the feasibility and acceptability of deprescribing N-of-1 trials and participant experiences. Directed content analysis methods were used to develop relevant categories and themes from interview transcript data. Transcripts were coded and analyzed by two team members, consulting additional members to establish consensus where needed. Inter-rater reliability between coders was established. The outcome measure data is the cumulative count of subjects who identified categories and themes from interview transcript data collected during the span of the outcome measure time frame, up to 6 times over 36 weeks.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "The maximum amount of time a subject could have been assessed for this outcome measure is 6 times across 36 weeks. This outcome was measured at each end of period visit (weeks 6, 12, 18, 24, 30) and at the end of intervention (weeks 12, 18, 24, 30, or 36)", "groups": [{"id": "OG000", "title": "Beta Blocker ABAB Sequence", "description": "This arm will follow an ABAB sequence. \"A\" representing ON beta blockers and \"B\" representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually up-titrating until reaching their home dose. Finally, during Period 4, we will again conduct a dose reduction until off of beta blockers.\n\nBeta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On \\[A\\] vs Off \\[B\\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.\n\nSubjects will be randomized into either ABAB or BABA sequences."}, {"id": "OG001", "title": "Beta Blocker BABA Sequence", "description": "This arm will follow a BABA sequence. \"A\" representing ON beta blockers and \"B\" representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers. Finally, during Period 4, we will up-titrate them back to their home dose of beta blockers.\n\nBeta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On \\[A\\] vs Off \\[B\\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.\n\nSubjects will be randomized into either ABAB or BABA sequences."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"title": "Technologic challenges related to the protocol", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Desire for study contact that balances safety and pragmatism", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Feedback on data visualization tool", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events were not assessed as part of this study which examined the feasibility and acceptability of deprescribing N-of-1 trials.", "description": "Adverse events were not assessed as part of this study which examined the feasibility and acceptability of deprescribing N-of-1 trials. This study record shares a protocol document and subject population with ClinicalTrials.gov record NCT04767061, which is a separate study. Adverse events data were collected and reported for this associated study in ClinicalTrials.gov record NCT04767061.", "eventGroups": [{"id": "EG000", "title": "Beta Blocker ABAB Sequence", "description": "This arm will follow an ABAB sequence. \"A\" representing ON beta blockers and \"B\" representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually up-titrating until reaching their home dose. Finally, during Period 4, we will again conduct a dose reduction until off of beta blockers.\n\nBeta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On \\[A\\] vs Off \\[B\\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.\n\nSubjects will be randomized into either ABAB or BABA sequences.", "deathsNumAffected": 0, "deathsNumAtRisk": 0, "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}, {"id": "EG001", "title": "Beta Blocker BABA Sequence", "description": "This arm will follow a BABA sequence. \"A\" representing ON beta blockers and \"B\" representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers. Finally, during Period 4, we will up-titrate them back to their home dose of beta blockers.\n\nBeta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On \\[A\\] vs Off \\[B\\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.\n\nSubjects will be randomized into either ABAB or BABA sequences.", "deathsNumAffected": 0, "deathsNumAtRisk": 0, "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Maryam Hyder", "organization": "Weill Cornell Medicine", "email": "mah4022@med.cornell.edu", "phone": "646-962-5904"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2022-12-27", "uploadDate": "2024-01-19T14:40", "filename": "Prot_SAP_001.pdf", "size": 740257}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2023-02-17", "uploadDate": "2024-01-27T13:19", "filename": "ICF_002.pdf", "size": 552755}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2024-02-28", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000054144", "term": "Heart Failure, Diastolic"}], "ancestors": [{"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9419", "name": "Heart Diseases", "asFound": "Heart Disease", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "asFound": "Heart Failure, Diastolic", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000011433", "term": "Propranolol"}, {"id": "D000008790", "term": "Metoprolol"}, {"id": "D000001262", "term": "Atenolol"}, {"id": "D000013015", "term": "Sotalol"}, {"id": "D000009248", "term": "Nadolol"}, {"id": "D000000070", "term": "Acebutolol"}, {"id": "D000077261", "term": "Carvedilol"}, {"id": "D000068577", "term": "Nebivolol"}, {"id": "D000017298", "term": "Bisoprolol"}, {"id": "D000007741", "term": "Labetalol"}, {"id": "D000010869", "term": "Pindolol"}, {"id": "D000015784", "term": "Betaxolol"}, {"id": "D000010394", "term": "Penbutolol"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}], "ancestors": [{"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000013565", "term": "Sympatholytics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000058671", "term": "Adrenergic beta-1 Receptor Antagonists"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}, {"id": "D000058665", "term": "Adrenergic beta-1 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000013566", "term": "Sympathomimetics"}, {"id": "D000012702", "term": "Serotonin Antagonists"}, {"id": "D000018490", "term": "Serotonin Agents"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "Circulating", "relevance": "HIGH"}, {"id": "M14298", "name": "Propranolol", "asFound": "Plaque", "relevance": "HIGH"}, {"id": "M276", "name": "Nebivolol", "asFound": "2.4", "relevance": "HIGH"}, {"id": "M10761", "name": "Labetalol", "asFound": "Mesenteric", "relevance": "HIGH"}, {"id": "M11762", "name": "Metoprolol", "asFound": "Max", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "asFound": "Elastography", "relevance": "HIGH"}, {"id": "M15817", "name": "Sotalol", "asFound": "Medication management", "relevance": "HIGH"}, {"id": "M19589", "name": "Bisoprolol", "asFound": "Gluconate", "relevance": "HIGH"}, {"id": "M13764", "name": "Pindolol", "asFound": "Pradaxa", "relevance": "HIGH"}, {"id": "M4568", "name": "Atenolol", "asFound": "Applicator", "relevance": "HIGH"}, {"id": "M18338", "name": "Betaxolol", "asFound": "DuoTrav", "relevance": "HIGH"}, {"id": "M12200", "name": "Nadolol", "asFound": "Poultry", "relevance": "HIGH"}, {"id": "M518", "name": "Acebutolol", "asFound": "Clearance rate", "relevance": "HIGH"}, {"id": "M13305", "name": "Penbutolol", "asFound": "Mandibular teeth", "relevance": "HIGH"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M16344", "name": "Sympatholytics", "relevance": "LOW"}, {"id": "M29197", "name": "Adrenergic beta-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}, {"id": "M15512", "name": "Serotonin", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}